Dr. Divya Bharathi S, Divya Bharathi S, Kannan J, Raja G, Pandidurai M, Arun Ramanan V, Karthikeyan S, Satheesh Kumar D, Kiranmayee N and Vasanth Rooban Narasimman
Introduction: Global Cancer Observatory 2020 reported that worldwide, lung cancer accounts for 11.40 percent of all cancer diagnoses and 18 percent of all cancer-related deaths. Reviewing the histological classification, the epidemiology of lung cancer in India has undergone significant changes over time. In India, information with respect to site wise conveyance of disease can be accumulated from populace based malignant growth libraries. The histological subtypes, on the other hand, are not reported by these data.
Methodology: This record based Ambispective (bidirectional) study was conducted among 394 lung cancer patients registered in a nodal centre located in Chennai, Tamil Nadu. The data pertaining to symptoms, co-morbidities, TNM staging, metastatic sites (if any), Superior vena cava obstruction, performance of PET CT, bronchoscopy, Histopathological class, Chemotherapy, radiotherapy & survival time were collected.
Results: More than half of the candidates (57%) were classified in stage IV A, according to American Joint Committee on Cancer (AJCC) staging manual 8th edition (Table 1). As per TNM staging, Metastasis was seen in 71% of the participants. Epidermal Growth Factor Receptor (EGFR) mutation was seen in 42% of candidates. On Histopathological examination majority of the candidates (60%) were found to have Adenocarcinoma.
Conclusion: Even though differences exist in the survival between lung cancer patients with chemo and without chemo, lung cancer patients with EGFR mutation and without the same and lung cancer patients with metastasis and without metastasis, the difference was not statistically significant.
Pages: 46-51 | 87 Views 25 Downloads